Ivan - from the SABCS website regarding Embargo...
"All authors must comply with the Symposium embargo policy, which states that no author is to provide information regarding the abstract or related research to be presented during the Symposium to the media or public prior to the scheduled time of presentation at the 2013 San Antonio Breast Cancer Symposium."
I've been researching this company for awhile and am about ready to take a position. I like the large amount of insider buys over the last year and a half. I followed LGND and bought when the insiders were loading up and it took off. On the trial side I have appreciated Ivan's insight and agree regarding the twice per week dosing.
Consider what the VP of Clinical Research - Dr. Imam El-Hariry (with 20 plus years of pharma exp and overseeing over 50 clinicals) said in the Q3 CC:
"I think the level of activity that I am seeing far exceeds that what I have seen in my past experience in any of the drugs that I also have taken to the market."
I'm hoping for a $4.75ish cost basis...if I can get it today.